MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

MDT

86.14

-0.25%↓

114.53

+0.54%↑

VEEV

172.83

-1.41%↓

HQY

83.37

+0.23%↑

PHR.US

8.39

+0.72%↑

Home・Akciju saraksts・Incyte Corp

Incyte Corp

Slēgts

SektorsVeselības aprūpe

94.35 0.56

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

93.66

Max

95.35

Galvenie mērījumi
By Trading Economics
Ienākumi	-125M 299M
Pārdošana	141M 1.5B
P/E Sektora vidējais	14.092 56.063
Peļņas marža	19.861
Darbinieki	2,844
EBITDA	-92M 415M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+21.63% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 28. apr.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-3.4B 18B
Iepriekšējā atvēršanas cena	93.79
Iepriekšējā slēgšanas cena	94.35

Ziņu noskaņojums

By Acuity

57%

43%

292 / 349 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

59.52 / 62.66 Atbalsts un pretestība

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 31. marts 23:31 UTC

Karstas akcijas

Stocks to Watch: Nike, RH, NCino

2026. g. 31. marts 22:35 UTC

Peļņas

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

2026. g. 1. apr. 00:00 UTC

Iegādes, apvienošanās, pārņemšana

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

2026. g. 31. marts 23:50 UTC

Iegādes, apvienošanās, pārņemšana

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

2026. g. 31. marts 23:43 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

2026. g. 31. marts 23:33 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

2026. g. 31. marts 23:21 UTC

Peļņas

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

2026. g. 31. marts 23:14 UTC

Tirgus saruna

Peļņas

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

2026. g. 31. marts 23:12 UTC

Tirgus saruna

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke 2025 Loss Widens >000002.SZ

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

2026. g. 31. marts 22:36 UTC

Peļņas

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

2026. g. 31. marts 21:46 UTC

Iegādes, apvienošanās, pārņemšana

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

2026. g. 31. marts 21:36 UTC

Tirgus saruna

West African Resources's Costs Higher Than Bull Expected -- Market Talk

2026. g. 31. marts 21:35 UTC

Peļņas

Nike Expects China Sales Down 20% in 4Q, CFO Says

2026. g. 31. marts 21:35 UTC

Peļņas

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

2026. g. 31. marts 21:35 UTC

Peļņas

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

2026. g. 31. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

2026. g. 31. marts 21:33 UTC

Peļņas

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

2026. g. 31. marts 21:32 UTC

Peļņas

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

2026. g. 31. marts 21:28 UTC

Peļņas

Nike Expects to End 4Q With Elevated Inventory, CFO Says

2026. g. 31. marts 21:26 UTC

Peļņas

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

2026. g. 31. marts 21:25 UTC

Peļņas

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

2026. g. 31. marts 21:24 UTC

Tirgus saruna

Peļņas

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

2026. g. 31. marts 21:22 UTC

Peļņas

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

2026. g. 31. marts 21:22 UTC

Peļņas

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

2026. g. 31. marts 21:21 UTC

Peļņas

Nike's Digital Channel Still Too Promotional, CFO Says

2026. g. 31. marts 21:20 UTC

Peļņas

Nike CEO: Converse Remains Important to Portfolio

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

21.63% augšup

Prognoze 12 mēnešiem

Vidējais 109.87 USD 21.63%

Augstākais 135 USD

Zemākais 75 USD

Pamatojoties uz 17 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

17 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 17 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Incyte Corp — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

59.52 / 62.66Atbalsts un pretestība

Bullish events outweigh bearish events.

All events are bearish.

Noskaņojums

By Acuity

292 / 349 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation